Last reviewed · How we verify

Beijing Kawin Technology Share-Holding Co., Ltd. — Portfolio Competitive Intelligence Brief

Beijing Kawin Technology Share-Holding Co., Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
PEG-IFN-SA /RBV PEG-IFN-SA /RBV phase 3 Pegylated interferon-alpha with nucleoside analog Interferon-alpha receptor; viral RNA polymerase Virology/Infectious Disease
Pegasys /RBV Pegasys /RBV phase 3 Interferon alfa-2a (pegylated) + nucleoside analog combination Interferon-alpha receptor; HCV RNA-dependent RNA polymerase Virology/Hepatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Beijing Kawin Technology Share-Holding Co., Ltd.:

Cite this brief

Drug Landscape (2026). Beijing Kawin Technology Share-Holding Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/beijing-kawin-technology-share-holding-co-ltd. Accessed 2026-05-17.

Related